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TYPE 2 DIABETES mainly results from the defects in insulin secretion from pancreatic ␤-cells and insulin resistance in target tissues (37, 44, 49) . Under normal conditions, insulin secretion is tightly controlled by a variety of stimulatory, modulatory, and inhibitory factors. Glucose is the primary physiological secretagogue, whereas norepinephrine and somatostatin are major physiological inhibitors of insulin secretion (38) . Glucose generates both triggering and amplifying signals. The triggering pathway, also referred to as the ATP-dependent K ϩ (K ATP ) channel-dependent pathway, is well documented, whereas the mechanisms underlying the K ATP channel-independent amplification pathway(s) have yet to be established (20, 41, 42) .
There is increasing evidence to suggest that protein tyrosine kinases (PTKs) are involved in the regulation of insulin secretion (35, 40, 48) . However, the precise function of tyrosine kinases in secretion is not known. Some studies have demonstrated that tyrosine kinase inhibitors induce large increases in insulin secretion (40, 48) , although decreased release also has been reported (35) . The controversial findings may result from the possibility that different PTKs have different or even opposite effects on insulin secretion.
Tyrosine kinases are divided into the following two major groups: receptor and nonreceptor. The Src family belongs to the nonreceptor tyrosine kinase group. Several lines of evidence suggest that the members of this family play a role in the highly regulated exocytotic process: 1) Src is expressed at high levels and concentrated on secretory vesicles and the plasma membrane in cells that are specialized for exocytosis, such as neuronal and endocrine cells (13, 15) ; 2) It has been shown that Src family tyrosine kinases exert an inhibitory effect on neurotransmitter release from neuronal cells (33) . In particular, they may be specifically involved in the regulation of kiss-andrun mode of exocytosis in synaptosomes, likely by tonic inhibition of kiss-and-run mode of secretion (4); 3) Src kinases can be activated by protein tyrosine phosphatase-␣ (PTP␣; see Ref. 54 ). In INS-1E cells, overexpression of the wild-type PTP␣ reduced insulin secretion, whereas overexpression of a phosphatase-inactive mutant of PTP␣ improved insulin secretion (21); 4) Src family kinases may be regulated by myristoylation and dynamic palmitoylation, and protein acylation has been implicated in the mechanism of inhibition of insulin secretion (9); and 5) Src kinase pathways are important for the extracellular Ca 2ϩ -dependent pancreatic enzyme secretion from pancreatic acini (47) .
Neurotransmitter release and insulin secretion share many similar regulatory mechanisms (17) . We hypothesized that Src family tyrosine kinases, which play important roles in neurotransmitter release (33) , may also be involved in insulin secretion. Moreover, PTP␣, an activator of Src kinase, has been shown to have an inhibitory role in insulin secretion (21) . It is reasonable to propose that Src kinases may negatively regulate insulin secretion. Therefore, in the present study, we investigated the potential role of Src family tyrosine kinases in insulin secretion. We found that two structurally unrelated inhibitors of Src family tyrosine kinases, PP2 and SU-6656, potentiated Ca 2ϩ -dependent insulin secretion from both rat pancreatic islets and INS-1 cells. The results suggest that Src family tyrosine kinases exert an inhibitory effect on Ca 2ϩ -dependent insulin secretion.
MATERIALS AND METHODS
Materials. Glucose, norepinephrine, forskolin, 12-O-tetradecanoylphorbol 13-acetate (TPA), Gö-6976, protein G-agarose beads, and nitrendipine (NTD) were obtained from Sigma (St. Louis, MO). 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolol [3,4,d ]pyrimidine (PP2), 4-amino-7-phenylpyrazol [3,4,d] pyrimidine (PP3), and PD-98059 were purchased from Calbiochem.
Antibodies. Anti-Src monoclonal antibody (mAb) 327 was kindly provided by Dr David I. Shalloway (Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY). AntiSrc[pY 418 ]phosphospecific antibody was bought from Biosource.
Isolation of rat pancreatic islets.
Male Sprague-Dawley rats (250 -400 g) were used. Immediately after CO 2 asphyxiation, the pancreases were removed, and the islets were isolated by a collagenase digestion technique (24) . Krebs-Ringer bicarbonate HEPES buffer (KRBH) containing 129 mM NaCl, 5 mM NaHCO 3, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO 4, 2.5 mM CaCl2, 2.8 mM glucose, 10 mM HEPES, and 0.1% BSA at pH 7.4 was used for isolation and picking of the islets.
Measurements of insulin release from islets. Insulin release was measured under static incubation conditions at 37°C using batches of five size-matched islets per tube. Islets were first cultured in RPMI 1640 media that contains 5.6 mM glucose, supplemented with 10 mM HEPES, 10% FBS, 2 mM glutamine, 100 g/ml streptomycin, 100 U/ml penicillin, and 50 M ␤-mercaptoethanol at 37°C in a 95% air plus 5% CO 2 atmosphere for 3 h (or for the time indicated in the text) and preincubated in regular KRBH buffer for the following 60 min. The islets were then incubated for 15 or 30 min. PP2, PP3, and SU-6656 were included in both culture and preincubation periods. At the end of the incubations, samples were taken and kept at Ϫ20°C until radioimmunoassayed. Insulin secretion was usually expressed as fractional release, i.e., the percentage of the insulin content of the islets that was released.
Cell culture and measurements of insulin release for clonal cells. INS-1 cells were grown and maintained in monolayer culture in RPMI 1640 media that contains 11.1 mM glucose, supplemented with 10 mM HEPES, 10% FBS, 2 mM glutamine, 100 g/ml streptomycin, 100 U/ml penicillin, and 50 M ␤-mercaptoethanol at 37°C in a 95% air plus 5% CO 2 atmosphere. Under static incubation conditions, cells were grown in 16-mm-diameter wells until confluency was reached. The experimental conditions used were the same as those used for rat islets with the following three exceptions: 1) the total treatment time with PP2, PP3, SU-6656 and PD-98059 was 2 h, 2) for PP2 and PP3, the RPMI 1640 medium contained 11.1 mM glucose, and 3) for SU-6656 and PD-98059, cells were not cultured in RPMI medium, instead they were treated in KRBH buffer for 2 h in the presence or absence of SU-6656 and PD-98059 before incubation.
Treatment of INS-1 cells before kinase assay or immunoblotting. Tissue culture plates (60 or 35 mm in diameter) of INS-1 cells were washed two times in KRBH buffer. Preincubation was carried out at 37°C in KRBH buffer for 60 min (PP2 or PP3 were present in RPMI medium for 1 h and then in regular KRBH buffer for preincubation for another hour). After the medium was aspirated out, fresh KRBH buffer with or without test agents was used for the incubation conditions (KRBH alone with basal glucose conditions was used as the control). The timing of the incubations was 15 min. The reactions were stopped by removing the medium and washing the cells two times with cold PBS. After any leftover solution was completely aspirated out, the plates were incubated in lysis buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 1 g/ml pepstatin, and 60 g/ml aprotinin) and rocked at 4°C for 60 min. The samples were collected in 1.5-ml Eppendorf tubes and centrifuged at 15,000 revolutions/min for 15 min at 4°C, and the resulting supernatants were used in the experiments as the cell lysate.
SDS-PAGE and immunoblot analysis. Western blotting was done according to Biosource instructions with minor modifications as follows. Lysate was resuspended with an equal volume of Laemmli sample buffer (125 mM Tris, pH 6.8, 10% SDS, 10% glycerol, 0.006% bromphenol blue, 130 mM dithiothreitol, and 5% 2-mercaptoethanol) and boiled for 90 s. The samples (20 -40 g/lane with equal amounts of protein used for all samples in the same experiment) were then separated by SDS-PAGE and transferred electrophoretically to a polyvinylidene fluoride (PVDF) membrane. The transfer solution contained 20 mM Tris, 230 mM glycine, 0.01% SDS, and 20% methanol. The membrane was then blocked overnight at 4°C in Tris-buffered saline containing 20 mM Tris-Cl, pH 7.4, 0.9% NaCl, and 0.1% Tween 20, plus 5% BSA (TBST). Primary antibody incubations were carried out for 2 h at room temperature. After being washed with TBST buffer four times for 10 min each, the membrane was incubated with horseradish peroxidase-conjugated anti-rabbit IgG from donkey or horseradish peroxidase-conjugated anti-mouse IgG from goat for 2 h at room temperature as appropriate. Washing of the membrane was carried out as before, and the bands were visualized by chemiluminescence. For experiments that required quantification, the density of bands was analyzed using ␣ Image software.
Immunoprecipitation. The reactions were performed by first incubating anti-Src mAb327 with cell lysates of INS-1 cells, rat pancreatic islets, or NIH 3T3 cells (300 g/lane) for 2 h at 4°C with shaking. The materials were centrifuged, and the supernatant was incubated with protein G agarose beads overnight at 4°C with shaking. After several washes with lysis buffer, the samples were boiled, and the beads were removed by centrifugation. The samples were then loaded on gels for analysis. The PVDF membranes were probed with anti-Src mAb327.
Src kinase assay. Src kinase activity was determined as described with modification (1, 39, 54) . INS-1 cell lysates containing 1-2 mg of protein were first incubated with anti-Src mAb327 for 2 h at 4°C and then mixed with GammaBind Sepharose beads for another hour. Kinase activity in the immunoprecipitate was subsequently measured by using an Src assay kit (Upstate Biotechnology), following the manufacturer's instructions except that the reactions were terminated by adding 5ϫ SDS sample buffer.
Glucose oxidation. Glucose oxidation was measured as previously reported with minor modification (51) . In brief, groups of 25 islets (in duplicate) were cultured at 37°C for 3 h in RPMI medium containing 5.6 mM glucose in the presence or absence of PP2 as indicated. The islets were then preincubated in KRBH buffer in the presence or absence of PP2 for 1 h. After preincubation, islets were incubated in 150 l of KRBH buffer, to which 0.17 Ci D-[U-
14 C]glucose had been added as indicated for 30 min. At the end of the incubation, islet metabolism was terminated by adding 200 l of 0.1 M HCl to the incubation mixture.
14 CO2 was collected by 300 l of 1 M NaOH for 2-4 h at 37°C and measured by liquid scintillation spectrometry.
Statistical methods. All data are shown as means Ϯ SE. Statistical significance was evaluated by two-way ANOVA or t-tests as appropriate. Differences were considered significant at P Ͻ 0.05.
RESULTS

Expression of Src kinase in pancreatic ␤-cells.
There are limited reports on the existence and function of Src family tyrosine kinases in pancreatic ␤-cells. Ohnishi et al. (34) showed that the expression of Src gradually increased with postnatal development in rat pancreatic islets by immunohistochemical analysis. In insulin-producing RINm5F cells, c-Src was shown to be involved in the anti-apoptotic action of nitric oxide (45) . Activation of cellular (c)-Src was also implicated in glucagon-like peptide 1-induced pancreatic ␤-cell proliferation in INS (832/13) cells (8) . However, Src was reported as "not expressed" in rGIP-15, ␤TC-3, and INS (832/13) cells by the Kinetworks KPKS 1.0 Western blotting analysis (12) . Therefore, to clarify the confusion, it was necessary to examine the expression of Src kinase in our system before testing its function.
As demonstrated in Fig. 1 , the expression of Src kinase in INS-1 cells and rat pancreatic islets was confirmed by immunoprecipitation and immunoblotting analysis. In Fig. 1A , lysates of INS-1 cells, rat islets, and NIH 3T3 cells (which served as a positive control for the expression of Src kinase) were subjected to immunoprecipitation with anti-Src mAb327. Next, the immunoprecipitated protein was subjected to immunoblotting with anti-Src mAb327. In Fig. 1B , cell lysates were directly subjected to immunoblotting with anti-Src mAb327. A band corresponding to Src was present in the lysates of rat pancreatic islets, INS-1 cells, and NIH 3T3 cells but not in the absence of lysate or anti-Src mAb327. Taken together, both immunoprecipitation and the Src kinase activity assay confirmed the expression of Src kinase in insulin-secreting ␤-cells.
Effects of Src family tyrosine kinase inhibitors on insulin secretion in INS-1 cells and Src kinase activity.
The effects of PP2, a selective Src family tyrosine kinase inhibitor (19) , were examined in INS-1 cells. PP3, structurally related to PP2, does not inhibit Src family kinases and was used to control for potential nonspecific effects of PP2 (26) . Autophosphorylation of Tyr 418 is critical for the full activation of Src family tyrosine kinases (50) . The presence of activated c-Src in unstimulated INS-1 cells was detected by immunoblotting with a specific antibody for phospho-Tyr 418 -containing-Src (pY 418 ). KCl (40 mM) was used to depolarize the ␤-cell, stimulate Ca 2ϩ influx, and consequently induce Ca 2ϩ -dependent insulin secretion. As shown in Fig. 2 ; ⌬ ϭ Ϫ0.4 Ϯ 0.11; P Ͻ 0.05).
SU-6656, structurally different from PP2, is another selective Src family kinase inhibitor (5) . Figure 3A shows that SU-6656 reduced the level of active c-Src in INS-1 cells as detected with a specific antibody. As shown in Fig. 3B (30) . Their effects on insulin secretion are less well defined. Because Src has been reported to be an upstream activator of ERK1/2 (28), the next series of experiments was performed to determine whether the effects of Src family kinases on insulin secretion were through the Src-ERK pathway. We tested the effects of PD-98059, a specific inhibitor of ERK on insulin secretion (11) . PD-98059 binds to the inactive form of ERK and thus prevents its activation by upstream activators, such as Src. We found that 100 M PD-98059 markedly decreased the level of KCl-activated ERK as expected. However, PD-98059 (3-100 M) had no effect on KCl-induced insulin secretion Effects of Src family tyrosine kinase inhibitors on insulin secretion in rat pancreatic islets. The INS-1 cell is a ratderived insulin-secreting cell line. Although it somewhat reflects the situation in normal rat pancreatic islets, some aspects of protein expression and exocytotic characteristics differ between this cell line and islets. Thus the effects of PP2 were further tested in islets. As indicated in Fig. 4 , PP2 potentiated KCl-induced insulin secretion in a time-dependent and concentration-dependent manner. The maximal effect was obtained at The next experiments were carried out to test the effects of PP2 on glucose-stimulated insulin secretion from islets. As The effects of PP2 were further examined on the K ATP channel-independent pathway of ␤-cell signaling by incubating islets with KCl and diazoxide (27) . In the presence of KCl and diazoxide, PP2 increased 2.8 and 8.3 mM but not 20 mM glucose-stimulated insulin secretion. The result indicates that the augmenting effects of PP2 on insulin release are distal to the K ATP channel since PP2 could still increase insulin secretion when the K ATP channels were "clamped" open by diazoxide.
Another selective Src family tyrosine kinase inhibitor, SU-6656, also augmented KCl-induced insulin secretion from islets in a concentration-dependent manner (Fig. 6) Additional experiments were performed to test the effects of PP3 on islets under the same conditions as PP2. PP3 is structurally similar to PP2 but does not inhibit Src family tyrosine kinase activity (see Fig. 2 Protein kinase C or protein kinase A activation and subsequent phosphorylation of targets in ␤-cells can potentiate insulin release. PP2 was reported to mildly inhibit protein kinase A (PKA) and protein kinase C (PKC) activity in an in vitro assay (3). Thus further experiments were performed to test whether PP2 also influenced insulin secretion in the presence of activated PKC or PKA. As shown in Fig. 7 , PP2 changed neither TPA-nor forskolin-induced insulin secretion in the presence of 2.8 mM glucose. Moreover, the classical PKC (cPKC) inhibitor Gö-6976 (1 M) did not significantly affect the augmenting effects of PP2 on glucose-stimulated insulin release (control, 5.9 Ϯ 0.45 vs. Gö-6976, 5.1 Ϯ 0.59% of content 30 min Ϫ1 ; ⌬ ϭ Ϫ0.8 Ϯ 0.84; P ϭ 0.41). This further suggests that cPKC is not involved in PP2 effects. Taken together, the data indicate that the amplifying effect of PP2 on insulin secretion is exerted solely on Ca 2ϩ -stimulated secretion.
Effects of PP2 on glucose metabolism. In further studies on the mechanism underlying the effects of PP2 on insulin secretion, glucose oxidation was measured in rat pancreatic islets to investigate whether PP2 can drive glucose metabolism. 
DISCUSSION
Having established the expression of Src kinase in pancreatic islets and INS-1 cells, we sought to examine the potential roles of Src family kinases on insulin secretion. The presence of activated Src kinase in unstimulated ␤-cells was first detected using an antibody recognizing the positive regulatory autophophorylated site (pY 418 ). It was then found that, in INS-1 cells, the Src family kinase inhibitors PP2 and SU-6656, but not the inactive control compound PP3, reduced Src kinase activity and enhanced Ca 2ϩ -dependent but not basal insulin secretion. Likewise, and more importantly, in rat pancreatic islets, both PP2 and SU-6656, but not PP3, potentiated insulin secretion stimulated by glucose or KCl in a concentration-and time-dependent manner. This augmenting effect of the Src family kinase inhibitors was Ca 2ϩ dependent and abolished by L-type Ca 2ϩ channel blockade. Moreover, PP2 had no effects on insulin release evoked by PKA or PKC activation. The results indicate that Src family tyrosine kinases play an inhibitory role on Ca 2ϩ -dependent insulin secretion. The major drawback of using inhibitors is their potential nonspecificity. To circumvent this problem, two structurally different inhibitors of Src family kinases, PP2 and SU-6656 (3), were tested, and similar effects on insulin secretion were demonstrated. Also, PP3, which is inactive but structurally similar to PP2, was used as a control for potential nonspecific effects throughout the present study.
We then tried to pinpoint the underlying mechanisms for Src family kinase inhibitors to potentiate insulin secretion. 1) The first was glucose metabolism. The effect of PP2 on glucose metabolism is unlikely to be the mechanism for PP2-potentiated insulin secretion since PP2 did not increase glucose oxidation to boost the production of metabolic coupling factors in stimulus-secretion pathways. 2) Second was the K ATP channel. PP2 slightly reduced glucose oxidation, which could lead to a decrease in the ATP-to-ADP ratio and possible activation of the K ATP channel. If anything, this would tend to inhibit the action of glucose. Furthermore, PP2 was still able to potentiate 2.8 and 8.3 mM glucose-induced insulin secretion under K ATP channel-independent conditions by treating islets with KCl and diazoxide. It appears therefore that the augmenting effects of PP2 on insulin secretion are unlikely to be due to any interaction with the K ATP channel. 3) Third was adenylyl cyclase. Neither the literature nor our data with forskolin indicate that Src kinases can regulate adenylyl cyclase activity. 4) Fourth was PKC. Neither the activation of cPKC and novel PKCs with TPA nor the inhibition of cPKCs with Gö-6976 changed the PP2 effects on insulin secretion, indicating that these PKC activities are not necessary for the PP2 action under these conditions. 5) Last was insulin synthesis. Src family kinases are thought to be involved in gene transcription (43) . Nevertheless, their effects on insulin secretion seem not to be the result of changes in insulin synthesis because the insulin 2) In a similar exocytotic system, rat brain synaptosomes, PP1 (another selective Src family kinase inhibitor, structurally and functionally similar to PP2) had no effect on the intracellular Ca 2ϩ levels under either basal or KCl conditions but increased KCl-evoked Ca 2ϩ -dependent release of glutamate, again suggesting that the effects of PP1 on exocytosis are downstream of Ca 2ϩ influx (4). Taken together, the potentiating effects of Src family kinase inhibitors on insulin secretion are likely because of their action at a site distal to the elevation of [Ca 2ϩ ] i and are independent of glucose metabolism, K ATP channel, adenylyl cyclase, cPKC and novel PKC isoforms, and insulin synthesis. Moreover, the augmenting effects are Ca 2ϩ dependent. We next attempted to decode the signaling pathway for Src family kinase-mediated inhibition of insulin secretion. Src family kinases interact with a variety of protein targets such as ERK1/2, phosphatidylinositol 3-kinase (PI 3-kinase), dynamin, synapsin, Shc, focal adhesion kinase, and paxillin. Among them, ERK1/2 can be activated by glucose, glucagon-like peptide-1, KCl, insulin, and phorbol esters and inhibited by epinephrine (2, 6, 18, 23) . It was shown that high glucose acutely increased the rate of insulin gene transcription, but chronically (from 24 h) inhibited it; both effects were found to be ERK1/2 dependent (25). In our experiments, consistent with the study by Khoo and Cobb (22), we did not find any effects of ERK1/2 inhibition on insulin secretion in INS-1 cells. In contrast, under exactly the same condition, the Src family kinase inhibitor (SU-6656) significantly increased insulin exocytosis. These data exclude the Src-ERK pathway in the mechanisms responsible for the augmenting effects of Src family kinase inhibitors on insulin release. PI 3-kinase, another downstream effector of c-Src, is a possible candidate since several studies have shown that inhibitors of PI 3-kinase amplify insulin secretion from INS 832/13 cells and mouse and rat pancreatic islets (10, 14, 29, 32, 53) . Our own preliminary study also demonstrated that LY-294002, an inhibitor of PI 3-kinase, augmented glucose-stimulated insulin secretion in a concentration-dependent manner (data not shown). Other potential players include dynamin and synapsin, which interact with Src through SH3 domains (13, 15) . Dynamin, a GTPase (36), has well-established roles in endocytosis and actin cytoskeleton remodeling (31) . Even more relevant to the present study, Tsuboi et al. (46) reported that dynamin is critical for Ca 2ϩ -dependent "kiss-and-run" (cavicapture) exocytosis in insulin-secreting cells (46) , whereas Baldwin et al. (4) suggested that Src family tyrosine kinase negatively regulates the "kiss-and-run" mode of exocytosis in rat brain synaptosomes. Therefore, it is quite likely that Src family tyrosine kinase negatively regulates insulin exocytosis in pancreatic ␤-cells by interacting with dynamin, destabilizing its associations with adapter proteins and affecting cytoskeleton dynamics (7) . Such a Src-dynamin interaction would explain the independence from upstream signaling pathways of insulin stimulus-secretion coupling, which we observed for Src family kinase-mediated inhibition of insulin secretion. Despite these data with dynamin, there is also evidence suggesting a potential role of Ca 2ϩ /calmodulin-dependent phosphorylation of synapsin I in insulin secretion (52) . Thus the interaction that occurs between Src and synapsin provides another potential mechanism for how Src could influence Ca 2ϩ -dependent insulin secretion. In conclusion, using selective inhibitors of the Src family kinase, we demonstrated that reduced Src family kinase activity led to increased Ca 2ϩ -dependent insulin secretion. It suggests that, under normal conditions, the Src family kinases are involved in a tonic inhibition of insulin secretion. This pathway is likely acting at a point distal to the elevation of [Ca 2ϩ ] i and independent of ERK1/2, PKC, and PKA. Future work is needed to determine which member or members of the Src family kinases are responsible for the inhibitory action on insulin exocytosis and their mode of action. The augmenting effects of Src family kinase inhibitors on insulin secretion may shed some light on the design of new therapeutic agents for type 2 diabetes mellitus.
